Safety and efficacy of mirikizumab as induction and maintenance for inflammatory bowel disease in adult patients: a systematic review and meta-analysis

Abstract Background Mirikizumab, a monoclonal antibody targeting interleukin-23 (IL-23), was studied for adult patients with moderate-to-severe inflammatory bowel disease (IBD). However, conflicting evidence exists on its safety, efficacy and optimal dosing strategy. Aim To evaluate the safety and e...

Full beskrivning

Bibliografiska uppgifter

Huvudupphov:	Maryam Falah, Leen Alhamd, Fatma Bayoumi, Aisha Allah Diwaya, Enas Taha, Lamia Alkodami, Riham Alsutaif, Bushra Mohandes, Idris Sula, Muhammad Candragupta Jihwaprani, Fathiya El-Raey
Materialtyp:	Artigo
Språk:	Inglês
Utgiven:	SpringerOpen 2026-05-01
Serie:	The Egyptian Journal of Internal Medicine
Ämnen:	Mirikizumab IBD Crohn’s disease Ulcerative colitis IL-23
Länkar:	https://doi.org/10.1186/s43162-026-00643-w
Taggar:	Lägg till en tagg Inga taggar, Lägg till första taggen!